Scholar Rock will remove Novo Nordisk’s Bloomington, Indiana fill-finish facility from its apitegromab FDA application after the FDA classified an April 2026 inspection as Official Action Indicated (OAI). FDA review will now continue through a second U.S. fill-finish site. The
